| Age |
/ decade |
598 |
1.09 (0.98, 1.21) |
0.098 |
480 |
1.06 (0.95, 1.19) |
0.28 |
118 |
1.23 (0.95, 1.59) |
0.12 |
| Months, Castrat.-Sensitive Dz |
<12 mos vs ≥12 mos |
390 |
1.25 (0.97, 1.60) |
0.080 |
300 |
1.15 (0.87, 1.53) |
0.33 |
90 |
1.43 (0.80, 2.54) |
0.23 |
| Months, Dx-Mets |
<36 mos vs ≥36 mos |
474 |
0.94 (0.77, 1.16) |
0.57 |
370 |
0.90 (0.72, 1.14) |
0.40 |
104 |
1.03 (0.65, 1.65) |
0.89 |
| Alk Phos |
Log-transformed |
448 |
1.37 (1.19, 1.57) |
<0.001 |
367 |
1.31 (1.13, 1.52) |
<0.001 |
81 |
2.09 (1.32, 3.30) |
0.002 |
| LDH |
Log-transformed |
259 |
1.82 (1.32, 2.49) |
<0.001 |
194 |
1.60 (1.12, 2.28) |
0.009 |
65 |
2.15 (1.08, 4.30) |
0.030 |
| Neutrophils/Lymphocyte Ratio |
Log-transformed |
530 |
1.59 (1.36, 1.84) |
<0.001 |
435 |
1.60 (1.36, 1.88) |
<0.001 |
95 |
1.32 (0.85, 2.05) |
0.22 |
| Hemoglobin |
/ unit |
555 |
0.82 (0.77, 0.87) |
<0.001 |
450 |
0.81 (0.75, 0.86) |
<0.001 |
105 |
0.95 (0.81, 1.12) |
0.52 |
| Baseline PSA |
Log-transformed |
587 |
1.21 (1.14, 1.29) |
<0.001 |
476 |
1.20 (1.13, 1.28) |
<0.001 |
111 |
1.27 (1.07, 1.51) |
0.007 |
| Charlson Score |
/ unit≥10 vs <10 |
598 |
1.03 (0.99, 1.08)1.10 (0.92, 1.32) |
0.170.29 |
480 |
1.03 (0.98, 1.08)1.13 (0.92, 1.38) |
0.280.25 |
118 |
1.03 (0.90, 1.17)0.91 (0.58, 1.43) |
0.690.69 |
| Gleason Score |
≥8 vs <8 |
540 |
1.16 (0.96, 1.42) |
0.13 |
431 |
1.18 (0.94, 1.48) |
0.15 |
109 |
0.99 (0.63, 1.57) |
0.98 |
| Visceral Disease |
Yes vs No |
598 |
1.67 (1.18, 2.35) |
0.004 |
480 |
1.59 (1.05, 2.40) |
0.028 |
118 |
1.71 (0.89, 3.30) |
0.11 |
| Opiates |
Yes vs No |
587 |
0.98 (0.80, 1.21) |
0.85 |
476 |
1.07 (0.86, 1.34) |
0.52 |
111 |
0.52 (0.29, 0.94) |
0.030 |
| Treatment |
Enza vs Abi |
598 |
1.10 (0.87, 1.40) |
0.42 |
|
- |
|
|
- |
|
| Concomitant Statins |
Yes vs No |
598 |
0.57 (0.46, 0.71) |
<0.001 |
480 |
0.58 (0.45, 0.73) |
<0.001 |
118 |
0.61 (0.37, 1.01) |
0.052 |
| Statin Type |
Atorvastatin vs Other |
199 |
1.05 (0.75, 1.48) |
0.77 |
157 |
1.21 (0.82, 1.77) |
0.34 |
42 |
0.41 (0.12, 1.38) |
0.15 |
| Simvastatin Equivalent Dose |
/ mg |
123 |
1.00 (0.99, 1.01) |
0.51 |
100 |
0.99 (0.98, 1.01) |
0.28 |
23 |
1.03 (0.97, 1.08) |
0.33 |
| Use of a hydrophilic statin |
Yes vs No |
176 |
0.78 (0.52, 1.16) |
0.22 |
153 |
0.64 (0.42, 0.98) |
0.040 |
23 |
2.29 (0.63, 8.29) |
0.21 |
| Multivariable Model |
| Age |
/ decade |
387 |
1.10 (0.94, 1.29) |
0.25 |
319 |
1.09 (0.92, 1.30) |
0.33 |
68 |
1.30 (0.86, 1.98) |
0.21 |
|
Alk Phos |
Log-transformed |
1.24 (1.06, 1.46) |
0.008 |
1.21 (1.02, 1.43) |
0.031 |
2.98 (1.60, 5.58) |
<0.001 |
| Neutrophils/Lymphocyte Ratio |
Log-transformed |
1.56 (1.30, 1.89) |
<0.001 |
1.63 (1.33, 2.00) |
<0.001 |
0.93 (0.49, 1.76) |
0.82 |
| Hemoglobin |
/ unit |
0.85 (0.78, 0.93) |
<0.001 |
0.83 (0.76, 0.91) |
<0.001 |
1.04 (0.81, 1.35) |
0.75 |
| Baseline PSA |
Log-transformed |
1.13 (1.05, 1.22) |
0.002 |
1.13 (1.04, 1.22) |
0.003 |
1.35 (1.02, 1.79) |
0.038 |
| Charlson Score |
≥10 vs <10 |
0.95 (0.72, 1.24) |
0.69 |
0.96 (0.71, 1.30) |
0.81 |
0.79 (0.38, 1.65) |
0.53 |
| Gleason Score |
≥8 vs <8 |
1.13 (0.88, 1.45) |
0.34 |
1.16 (0.88, 1.54) |
0.29 |
1.52 (0.76, 3.03) |
0.24 |
| Visceral Disease |
Yes vs No |
1.93 (1.24, 3.01) |
0.004 |
1.81 (1.08, 3.03) |
0.025 |
3.25 (1.11, 9.53) |
0.032 |
| Opiate Use |
Yes vs No |
1.10 (0.85, 1.42) |
0.48 |
1.28 (0.97, 1.68) |
0.080 |
0.22 (0.09, 0.57) |
0.002 |
| Treatment |
Enza vs Abi |
0.91 (0.66, 1.25) |
0.56 |
- |
- |
- |
- |
| Concomitant Statins |
Yes vs No |
0.47 (0.35, 0.63) |
<0.001 |
0.45 (0.33, 0.62) |
<0.001 |
0.41 (0.19, 0.92) |
0.031 |
| 3-Month Landmark Analysis – Multivariable Model. |
| Age |
/ decade |
360 |
1.07 (0.91, 1.27) |
0.41 |
296 |
1.06 (0.88, 1.27) |
0.54 |
64 |
1.19 (0.77, 1.84) |
0.43 |
| Alk Phos |
Log-transformed |
1.15 (0.97, 1.36) |
0.12 |
1.11 (0.92, 1.33) |
0.27 |
3.13 (1.63, 6.02) |
<0.001 |
| Neutrophils/Lymphocyte Ratio |
Log-transformed |
1.51 (1.23, 1.85) |
<0.001 |
1.59 (1.27, 1.97) |
<0.001 |
0.93 (0.47, 1.83) |
0.83 |
| Hemoglobin |
/unit |
0.86 (0.78, 0.94) |
0.001 |
0.85 (0.77, 0.93) |
0.001 |
1.00 (0.75, 1.34) |
0.99 |
| Baseline PSA |
Log-transformed |
1.13 (1.05, 1.22) |
0.002 |
1.13 (1.04, 1.22) |
0.004 |
1.33 (0.97, 1.84) |
0.078 |
| Charlson Score |
≥10 vs <10 |
0.93 (0.70, 1.22) |
0.59 |
0.97 (0.71, 1.33) |
0.86 |
0.75 (0.34, 1.62) |
0.46 |
| Gleason Score |
≥8 vs <8 |
1.16 (0.89, 1.51) |
0.26 |
1.25 (0.93, 1.69) |
0.14 |
1.17 (0.56, 2.43) |
0.67 |
| Visceral Disease |
Yes vs No |
2.05 (1.28, 3.30) |
0.003 |
1.79 (1.02, 3.13) |
0.043 |
3.61 (1.12,10.86) |
0.023 |
| Opiates |
Yes vs No |
1.16 (0.89, 1.51) |
0.28 |
1.27 (0.96, 1.69) |
0.099 |
0.30 (0.11, 0.79) |
0.015 |
| Treatment |
Enza vs Abi |
0.86 (0.62, 1.20) |
0.38 |
- |
- |
- |
- |
| ≥3 Months of Continuous Use Statins |
Yes vs No |
0.53 (0.39, 0.72) |
<0.001 |
0.51 (0.37, 0.72) |
<0.001 |
0.49 (0.20, 1.24) |
0.13 |
